Total Long Term Debt (Quarterly) Chart

View Total Long Term Debt (Quarterly) for VRTX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Total Long Term Debt (Quarterly) Chart
Start Trial

Historical Total Long Term Debt (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 1.978B
March 31, 2026 1.986B
December 31, 2025 1.959B
September 30, 2025 1.835B
June 30, 2025 1.527B
March 31, 2025 1.649B
December 31, 2024 1.662B
September 30, 2024 1.703B
June 30, 2024 933.40M
March 31, 2024 721.30M
December 31, 2023 775.30M
September 30, 2023 744.70M
June 30, 2023 767.60M
March 31, 2023 789.20M
December 31, 2022 851.10M
September 30, 2022 824.60M
June 30, 2022 847.30M
March 31, 2022 872.50M
December 31, 2021 934.10M
September 30, 2021 876.80M
June 30, 2021 893.85M
March 31, 2021 898.80M
December 31, 2020 931.94M
September 30, 2020 546.51M
June 30, 2020 522.07M
Date Value
March 31, 2020 532.95M
December 31, 2019 661.66M
September 30, 2019 641.60M
June 30, 2019 649.01M
March 31, 2019 659.59M
December 31, 2018 591.37M
September 30, 2018 588.04M
June 30, 2018 592.74M
March 31, 2018 595.12M
December 31, 2017 606.43M
September 30, 2017 587.19M
June 30, 2017 568.54M
March 31, 2017 548.40M
December 31, 2016 540.76M
September 30, 2016 820.32M
June 30, 2016 820.63M
March 31, 2016 824.49M
December 31, 2015 826.53M
September 30, 2015 820.98M
June 30, 2015 824.47M
March 31, 2015 833.91M
December 31, 2014 824.95M
September 30, 2014 828.24M
June 30, 2014 538.03M
March 31, 2014 541.18M

Total Long Term Debt Definition

Represents a company's total debt maturing for more than 12 months of the reporting period.

Read full definition.

Total Long Term Debt (Quarterly) Range, Past 5 Years

View Total Long Term Debt (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Total Long Term Debt (Quarterly) Benchmarks

View Total Long Term Debt (Quarterly) Benchmarks
Start Trial
Gilead Sciences, Inc. 26.25B
Alnylam Pharmaceuticals, Inc. 2.942B
Sionna Therapeutics, Inc. 6.692M
Regeneron Pharmaceuticals, Inc. 2.707B
Biogen, Inc. 8.355B